Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17783831 | 0.89 | ROCK2 (1.00) | AAK1ROCK2 | |
| SCHEMBL18334798 | 0.89 | AAK1 (0.80) | AAK1ROCK2 | |
| SCHEMBL15972857 | 0.87 | AAK1 (1.00) | AAK1ROCK2 | |
| SCHEMBL15973152 | 0.87 | AAK1 (1.00) | AAK1ROCK2 | |
| SCHEMBL15972992 | 0.87 | AAK1 (1.00) | AAK1ROCK2 | |
| SCHEMBL15973581 | 0.85 | AAK1 (1.00) | AAK1ROCK2 | |
| SCHEMBL17783799 | 0.84 | ROCK2 (1.00) | ROCK2 | |
| SCHEMBL15973065 | 0.84 | AAK1 (0.76) | AAK1ROCK2 | |
| SCHEMBL15972221 | 0.84 | AAK1 (1.00) | AAK1ROCK2 | |
| SCHEMBL15972153 | 0.84 | AAK1 (1.00) | AAK1ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9708337-B2 | Aryl amide-based kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-07-18 | — | — | US | claimed |
| EP-2958924-B1 | 5H-CHROMENO[3,4-C]PYRIDINES AS INHIBITORS OF ADAPTOR ASSOCIATED KINASE 1 (AAK1) | BRISTOL MYERS SQUIBB CO (US) | 2016-12-28 | — | — | EP | claimed |
| US-20160016967-A1 | ARYL AMIDE-BASED KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2016-01-21 | — | — | US | claimed |
| US-9708337-B2 | Aryl amide-based kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-07-18 | — | — | US | disclosed |
| US-9708337-B2 | Aryl amide-based kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-07-18 | — | — | US | disclosed |
| US-9708337-B2 | Aryl amide-based kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-07-18 | — | — | US | disclosed |
| EP-2958924-B1 | 5H-CHROMENO[3,4-C]PYRIDINES AS INHIBITORS OF ADAPTOR ASSOCIATED KINASE 1 (AAK1) | BRISTOL MYERS SQUIBB CO (US) | 2016-12-28 | — | — | EP | disclosed |
| US-20160016967-A1 | ARYL AMIDE-BASED KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2016-01-21 | — | — | US | disclosed |
| US-20160016967-A1 | ARYL AMIDE-BASED KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2016-01-21 | — | — | US | disclosed |
| US-20160016967-A1 | ARYL AMIDE-BASED KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2016-01-21 | — | — | US | disclosed |
| EP-2958924-A1 | 5H-CHROMENO[3,4-C]PYRIDINES AS INHIBITORS OF ADAPTOR ASSOCIATED KINASE 1 (AAK1) | Bristol-Myers Squibb Company (US) | 2015-12-30 | — | — | EP | disclosed |
| WO-2014130258-A1 | 5H-CHROMENO[3,4-C]PYRIDINES AS INHIBITORS OF ADAPTOR ASSOCIATED KINASE 1 (AAK1) | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-08-28 | — | — | WO | disclosed |
| WO-2014130258-A1 | 5H-CHROMENO[3,4-C]PYRIDINES AS INHIBITORS OF ADAPTOR ASSOCIATED KINASE 1 (AAK1) | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160016967-A1 | ARYL AMIDE-BASED KINASE INHIBITORS | AAK1, ADCK1, NCK1 | AAK1 1/4885ROCK2 1050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.